ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P47-16 New Drug-Related Prior Authorization Requirements for Botulinum Toxin, Remicade, Rituxan and Biologic Immunomodulators
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအီးကထိဘၢၣ် 10, 2016
လံာ်တီလံာ်မီတဖၣ်ဒီး လံာ်ကွီၣ်ဒိတဖၣ်အစၢတဖၣ်
တၢ်ပာ်ဖျါ 2941 - 2950 လၢ 3607 အစၢတဖၣ်အကျါ
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P56-17 Implementation of a Medical Drug Exclusions List
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအီးကထိဘၢၣ် 16, 2017
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P5R1-17 Updated: Third Party Payments of Premium and/or Cost-Sharing
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါယူၤလံ 05, 2017
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P50-16 Addition of a Drug (Xiidra) to the Ophthalmic Immunomodulators Prior Authorization with Quantity Limit Program
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအီးကထိဘၢၣ် 28, 2016
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P53-16 New Notification Requirement for Outpatient Dialysis Services for Commercial Products and Subscribers in Government Programs
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါနိၣ်၀့ဘၢၣ် 09, 2016
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P43R1-16 Updated: Third Party Payments of Premium and/or Cost-Sharing
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါနိၣ်၀့ဘၢၣ် 01, 2016
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P6-17 A New Drug, Emflaza (deflazacort), Will Require Prior Authorization
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါဖ့ၤဘြူၤအါရံၤ 27, 2017
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P46-16 Changes in Medical Policy IV-87 Spinal Fusion: Lumbar
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါစဲးပတ့ဘၢၣ် 30, 2016
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P17-17 Addition of Drug Kisqali to the Self-Administered Oncology Prior Authorization with Quantity Limit Program
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအ့ဖြ့ၣ် 28, 2017
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P22-17 Identified Claims Processing Issues Grid
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါမ့ၤ 10, 2017